999 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Acquired by Adell Harriman & Carpenter Inc.

Adell Harriman & Carpenter Inc. bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 999 shares of the company’s stock, valued at approximately $413,000.

Several other large investors also recently added to or reduced their stakes in IDXX. International Assets Investment Management LLC raised its holdings in IDEXX Laboratories by 52,746.0% in the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock worth $2,669,890,000 after acquiring an additional 527,460 shares during the period. Assenagon Asset Management S.A. grew its holdings in IDEXX Laboratories by 265.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock valued at $179,867,000 after buying an additional 316,048 shares during the last quarter. Seilern Investment Management Ltd bought a new position in IDEXX Laboratories in the 4th quarter worth approximately $113,104,000. Vontobel Holding Ltd. increased its position in IDEXX Laboratories by 90.1% during the fourth quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company’s stock worth $173,051,000 after acquiring an additional 198,404 shares during the period. Finally, Worldquant Millennium Advisors LLC raised its position in shares of IDEXX Laboratories by 230.1% during the third quarter. Worldquant Millennium Advisors LLC now owns 110,196 shares of the company’s stock valued at $55,673,000 after buying an additional 76,809 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Trading Down 3.3 %

IDXX stock opened at $444.53 on Friday. The business has a fifty day moving average of $430.77 and a 200-day moving average of $453.31. The company has a market cap of $36.40 billion, a P/E ratio of 41.66, a PEG ratio of 3.47 and a beta of 1.37. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The company has a quick ratio of 1.03, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,330 shares of company stock worth $6,161,276. Company insiders own 2.11% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on IDXX. Leerink Partners began coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. Piper Sandler raised their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, February 5th. Morgan Stanley dropped their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Finally, Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.